Overview

Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes

Status:
Unknown status

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

In this proposal,the investigators will examine whether the selectivity of eplerenone for the MR will translate into a better glucose and metabolic profile compare to spironolactone in patients with HF with glucose intolerance or type 2 diabetes. In addition, the investigators will also compare the impact of these two agents on changes of concentrations of established prognostic biomarkers of neurohormonal activation and extracellular matrix turnover.

Phase:

Phase 3

Details

Lead Sponsor:

Montreal Heart Institute

Collaborator:

Pfizer

Treatments:

Eplerenone
Spironolactone